Aytu BioScience

Aytu BioPharma is a publicly traded, commercial-stage biopharmaceutical company with a distinct focus on complex CNS conditions, including MDD and ADHD. Its strategy centers on acquiring, in-licensing, and commercializing novel therapeutics, supported by a best-in-class patient access platform, Aytu RxConnect. The company has built a portfolio of FDA-approved products, most notably the recently launched antidepressant EXXUA™ (gepirone), while managing a legacy portfolio of pediatric and other specialty products. Aytu's hybrid model generates revenue from commercial sales to fund operations and strategic growth initiatives.

Aytu's platform is its integrated commercial and development engine focused on identifying, acquiring, and commercializing late-stage or approved therapeutic assets for CNS disorders, supported by its proprietary patient support program, Aytu RxConnect.

Aytu competes in the massive, generic-dominated antidepressant and ADHD markets. It differentiates through novel mechanisms (EXXUA's gepirone), convenient formulations (ODTs for ADHD), and a high-touch commercial and patient support strategy, rather than competing on scale alone.